ALT levels ≥ monthly for 6 months after initiation; every 6–8 weeks thereafter
Platelet count, white blood cell count, and hemoglobin or hematocrit monitored at baseline and monthly for 6 months after initiation and every 6–8 weeks thereafter
LFT at baseline and every 2 weeks during the first 3 months, monthly during the second 3 months, and every 3 months or as needed thereafter
CBC with differential at baseline and every 2 weeks during the first 3 months, monthly during the second 3 months, and every 3 months or as needed thereafter
ACR, American College of Rheumatology; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BSR, British Society for Rheumatology; CBC, complete blood count; DMARD, disease-modifying antirheumatic drug; HCQ/CQ, hydroxychloroquine/chloroquine; LFT, liver function test; MTX, methotrexate; N/A, not available; PI, prescribing information; RA, rheumatoid arthritis; ref, reference. , infliximab, etanercept, golimumab, certolizumab, abatacept, and anakinra do not currently have a laboratory monitoring program; patients receiving these medications should follow the laboratory monitoring guidelines for any coadministered medications. , golimumab, and rituximab are indicated for RA only in combination with methotrexate. -associated toxicity is dependent on lifetime cumulative dose and average daily dose. the time of this review, monitoring guidelines for baricitinib and sarilumab have not been established.